Exploring Testosterone Replacement Therapy and Tools for Predicting Cancer Aggressiveness
In a recent episode of “The Drive,” internationally recognized urologist Ted Schaeffer, M.D., Ph.D., delves into the intricate relationship between testosterone and prostate cancer. Schaeffer provides a comprehensive overview of the TRAVERSE trial, highlighting the complex dynamics between exogenous testosterone and prostate cancer risk. He explains the androgen receptor saturation theory and discusses how varying levels of testosterone affect different organs. Schaeffer also sheds light on the Decipher test, a crucial tool for assessing cancer aggressiveness and guiding personalized treatment strategies. Moreover, he addresses the safe administration of testosterone replacement therapy (TRT) in patients with low-grade prostate cancer and discusses advancements in prostate cancer therapies and biomarkers, such as PSA, that help develop precise treatment strategies while minimizing the need for broad androgen deprivation therapy. This episode offers valuable insights into the role of testosterone in prostate cancer, helping patients and clinicians make informed decisions about treatment options.
